TY - JOUR
T1 - Improving Infant Hydrocephalus Outcomes in Uganda
T2 - A Longitudinal Prospective Study Protocol for Predicting Developmental Outcomes and Identifying Patients at Risk for Early Treatment Failure after ETV/CPC
AU - Vadset, Taylor A.
AU - Rajaram, Ajay
AU - Hsiao, Chuan Heng
AU - Kemigisha Katungi, Miriah
AU - Magombe, Joshua
AU - Seruwu, Marvin
AU - Nsubuga, Brian Kaaya
AU - Vyas, Rutvi
AU - Tatz, Julia
AU - Playter, Katharine
AU - Nalule, Esther
AU - Natukwatsa, Davis
AU - Wabukoma, Moses
AU - Neri Perez, Luis E.
AU - Mulondo, Ronald
AU - Queally, Jennifer T.
AU - Fenster, Aaron
AU - Kulkarni, Abhaya V.
AU - Schiff, Steven J.
AU - Grant, Patricia Ellen
AU - Kabachelor, Edith Mbabazi
AU - Warf, Benjamin C.
AU - Sutin, Jason D.B.
AU - Lin, Pei Yi
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1
Y1 - 2022/1
N2 - Infant hydrocephalus poses a severe global health burden; 80% of cases occur in the developing world where patients have limited access to neurosurgical care. Surgical treatment combining endoscopic third ventriculostomy and choroid plexus cauterization (ETV/CPC), first practiced at CURE Children’s Hospital of Uganda (CCHU), is as effective as standard ventriculoperitoneal shunt (VPS) placement while requiring fewer resources and less post-operative care. Although treatment focuses on controlling ventricle size, this has little association with treatment failure or long-term outcome. This study aims to monitor the progression of hydrocephalus and treatment response, and investigate the association between cerebral physiology, brain growth, and neurodevelopmental outcomes following surgery. We will enroll 300 infants admitted to CCHU for treatment. All patients will receive pre/post-operative measurements of cerebral tissue oxygenation (SO2 ), cerebral blood flow (CBF), and cerebral metabolic rate of oxygen consumption (CMRO2 ) using frequency-domain near-infrared combined with diffuse correlation spectroscopies (FDNIRS-DCS). Infants will also receive brain imaging, to monitor tissue/ventricle volume, and neurodevelopmental assessments until two years of age. This study will provide a foundation for implementing cerebral physiological monitoring to establish evidence-based guidelines for hydrocephalus treatment. This paper outlines the protocol, clinical workflow, data management, and analysis plan of this international, multi-center trial.
AB - Infant hydrocephalus poses a severe global health burden; 80% of cases occur in the developing world where patients have limited access to neurosurgical care. Surgical treatment combining endoscopic third ventriculostomy and choroid plexus cauterization (ETV/CPC), first practiced at CURE Children’s Hospital of Uganda (CCHU), is as effective as standard ventriculoperitoneal shunt (VPS) placement while requiring fewer resources and less post-operative care. Although treatment focuses on controlling ventricle size, this has little association with treatment failure or long-term outcome. This study aims to monitor the progression of hydrocephalus and treatment response, and investigate the association between cerebral physiology, brain growth, and neurodevelopmental outcomes following surgery. We will enroll 300 infants admitted to CCHU for treatment. All patients will receive pre/post-operative measurements of cerebral tissue oxygenation (SO2 ), cerebral blood flow (CBF), and cerebral metabolic rate of oxygen consumption (CMRO2 ) using frequency-domain near-infrared combined with diffuse correlation spectroscopies (FDNIRS-DCS). Infants will also receive brain imaging, to monitor tissue/ventricle volume, and neurodevelopmental assessments until two years of age. This study will provide a foundation for implementing cerebral physiological monitoring to establish evidence-based guidelines for hydrocephalus treatment. This paper outlines the protocol, clinical workflow, data management, and analysis plan of this international, multi-center trial.
UR - http://www.scopus.com/inward/record.url?scp=85123206698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123206698&partnerID=8YFLogxK
U2 - 10.3390/metabo12010078
DO - 10.3390/metabo12010078
M3 - Article
C2 - 35050201
AN - SCOPUS:85123206698
SN - 2218-1989
VL - 12
JO - Metabolites
JF - Metabolites
IS - 1
M1 - 78
ER -